CVRX - NASDAQ

CVRx, Inc.

CVRX·NASDAQ

$5.39

-1.3%

HealthcareMedical - Devices

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$143.03M

EPS-2.0400

P/E Ratio-2.64

Earnings Date08/03/2026

104.79M

Assets

-21%

3Y-16.0%

5Y+62.0%

10Y+260.0%

65.47M

Total Liabilities

3Y+315.0%

5Y-82.0%

10Y-79.0%

39.32M

Total Equity

-45%

3Y-64.0%

5Y-113.0%

10Y-114.0%

CVRx, Inc. Funding & Solvency Profile

CVRX · NASDAQ

Current Assets

Cash & Cash Equivalents75.71M

Net Receivables10.66M

Inventory12.21M

Other Current Assets3.07M

Total Current Assets102 M

Non-Current Assets

Property, Plant & Equipment3.12M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets26.00K

Total Non-Current Assets3 M

Total Assets

104.79M

Financial Health Analysis

Current Ratio

7.63x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.66x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

88 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

97% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

CVRx, Inc. Balance Sheet

CVRX • NASDAQ

CVRx, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	75.7M	105.9M	90.6M	106.2M	142.1M	59.1M	25.7M
Cash & Short-Term Investments	75.7M	105.9M	90.6M	106.2M	142.1M	59.1M	25.7M
Net Receivables	10.7M	9.3M	7.6M	5.5M	2.6M	1.3M	719K
Accounts Receivables	10.7M	9.3M	7.6M	5.5M	2.6M	1.3M	719K
Inventory	12.2M	12.1M	11M	7M	3.9M	3.3M	2.1M
Prepaids	0.0	0.0	0.0	0.0	0.0	605K	375K
Other Current Assets	3.1M	2.5M	3M	4.2M	2.6M	0.0	375K
Total Current Assets	101.6M	129.8M	112.1M	122.9M	151.1M	64.3M	28.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3.1M	3.6M	3.1M	2M	1.4M	410K	174K
Other Non-Current Assets	26K	27K	27K	27K	26K	26K	26K
Total Non-Current Assets	3.1M	3.6M	3.1M	2.1M	1.5M	436K	200K
Total Assets	104.8M	133.4M	115.2M	124.9M	152.5M	64.8M	29.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.8M	2.7M	2M	1.8M	861K	525K	437K
Accounts Payable	3.8M	2.6M	1.9M	1.7M	510K	483K	437K
Other Payables	0.0	135K	125K	120K	351K	42K	0.0
Accrued Expenses	0.0	2.1M	1.5M	2.8M	2.7M	2.2M	1.1M
Capital Lease Obligations (Current)	0.0	282K	231K	222K	0.0	0.0	0.0
Tax Payables	0.0	135K	125K	120K	351K	42K	0.0
Other Current Liabilities	9.5M	5.7M	4.1M	3.3M	2.3M	5.3M	7.1M
Total Current Liabilities	13.3M	10.8M	7.9M	8.1M	5.9M	8M	8.6M
NON-CURRENT LIABILITIES
Long Term Debt	50.2M	49.3M	29.2M	6.7M	0.0	19.3M	19M
Other Non-Current Liabilities	1.4M	1.4M	1M	805K	681K	330.8M	280.5M
Total Non-Current Liabilities	52.2M	51.6M	31.4M	7.7M	681K	350M	299.5M
Capital Lease Obligations	638K	1.2M	1.4M	339K	0.0	0.0	0.0
Total Liabilities	65.5M	62.4M	39.3M	15.8M	6.6M	358M	308.2M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	280M
Common Stock	263K	253K	209K	207K	204K	4K	5K
Additional Paid-In Capital	629.9M	608.4M	553.3M	545.4M	540.7M	58.6M	58.5M
Retained Earnings	-590.7M	-537.3M	-477.4M	-436.2M	-394.8M	-351.7M	-337.6M
Accumulated Other Comprehensive Income/Loss	-203K	-206K	-207K	-207K	-198K	-190K	-189K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	187K
Total Stockholders' Equity	39.3M	71.1M	75.9M	109.2M	146M	-293.2M	-279M
Total Equity	39.3M	71.1M	75.9M	109.2M	146M	-293.2M	-279M
SUMMARY
Total Liabilities & Equity	104.8M	133.4M	115.2M	124.9M	152.5M	64.8M	29.1M
Total Debt	50.8M	50.4M	30.6M	7.1M	0.0	19.3M	19M
Net Debt	-24.9M	-55.5M	-60M	-99.1M	-142.1M	-39.8M	-6.7M
Shares Outstanding	26,151,700	26,151,700	26,151,700	26,151,700	26,151,700	26,151,700	26,151,700

SEC Filings

CVRX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 01, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 20, 2026	June 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 13, 2026	April 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	February 27, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 13, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 12, 2026	February 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing

Showing 1 to 10 of 76 filings

Related Guides

Blog Categories

Continue your CVRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.